Skip to Content
Merck
All Photos(1)

Key Documents

C3160

Sigma-Aldrich

Complement C5 from human serum

≥90% (SDS-PAGE), >100,000 C5H50 units/mg protein

Synonym(s):

C5 human, Complement C5

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
MDL number:
UNSPSC Code:
12352202
NACRES:
NA.71

biological source

human serum

Quality Level

Assay

≥90% (SDS-PAGE)

form

solution

specific activity

>100,000 C5H50 units/mg protein

concentration

1 mg/mL in PBS, pH 7.2

technique(s)

activity assay: suitable

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... C5(727)

Application

Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis.

Biochem/physiol Actions

Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000.

Quality

Functionally active by a sensitive hemolytic assay.

Other Notes

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The role of complement inhibition in PNH.
Hillmen P.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2008(1), 116-123 (2008)
Peter Hillmen et al.
The New England journal of medicine, 350(6), 552-559 (2004-02-06)
Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement
A M Risitano et al.
Mini reviews in medicinal chemistry, 11(6), 528-535 (2011-05-13)
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evident chronic hemolysis due to the absence of the complement regulators CD55 and CD59 on PNH

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service